
Chinese General Practice ›› 2025, Vol. 28 ›› Issue (15): 1932-1936.DOI: 10.12114/j.issn.1007-9572.2024.0376
Special Issue: 高血压最新文章合辑
• Review & Perspectives • Previous Articles
Received:2024-05-24
Revised:2024-10-24
Published:2025-05-20
Online:2025-03-21
Contact:
SHI Tieying
通讯作者:
史铁英
作者简介:作者贡献:
隋鸿平负责文章的构思与设计、研究资料的收集与整理、论文撰写;李婷婷、姜桐桐负责论文修订、文章的质量控制及审校;夏云龙、史铁英对文章整体负责,监督管理。
基金资助:
Add to citation manager EndNote|Ris|BibTeX
URL: https://www.chinagp.net/EN/10.12114/j.issn.1007-9572.2024.0376
| [1] |
|
| [2] |
|
| [3] |
|
| [4] |
|
| [5] |
王欢,马松涛,肖洪涛,等. 贝伐珠单抗相关性高血压的研究现状[J]. 中国临床药理学杂志,2024,40(5):763-767. DOI:10.13699/j.cnki.1001-6821.2024.05.028.
|
| [6] |
|
| [7] |
边波,王雪竹. 抗肿瘤药物引起高血压的机制及其处理措施研究进展[J]. 中华高血压杂志,2023,31(2):111-115. DOI:10.16439/j.issn.1673-7245.2023.02.004.
|
| [8] |
|
| [9] |
|
| [10] |
中华医学会妇科肿瘤学分会. 妇科肿瘤抗血管内皮生长因子单克隆抗体临床应用指南(2022版)[J]. 现代妇产科进展,2023,32(1):1-13. DOI:10.13283/j.cnki.xdfckjz.2023.01.001.
|
| [11] |
邱鲁鹏,孙卓雅,赵晓,等. 抗血管生成药物联合免疫检查点抑制剂治疗非小细胞肺癌的作用机制及临床应用进展[J]. 解放军医学院学报,2022,43(12):1288-1292,1297. DOI:10.3969/j.issn.2095-5227.2022.12.016.
|
| [12] |
|
| [13] |
National Cancer Institute. Common Terminology Criteria for Adverse Events(CTCAE)v.5.0. 2017[A/OL].(2017-11-27)[2024-04-28].
|
| [14] |
|
| [15] |
徐雯静,陈宁,甄健存. 贝伐珠单抗相关不良反应的文献分析[J]. 现代药物与临床,2022,37(2):415-419. DOI:10.7501/j.issn.1674-5515.2022.02.035.
|
| [16] |
|
| [17] |
|
| [18] |
|
| [19] |
|
| [20] |
|
| [21] |
|
| [22] |
|
| [23] |
|
| [24] |
|
| [25] |
|
| [26] |
隋鸿平,王蕊,李婷婷,等. 家庭血压监测及管理研究进展[J]. 中华护理杂志,2023,58(22):2801-2806. DOI:10.3761/j.issn.0254-1769.2023.22.016.
|
| [27] |
|
| [28] |
中华医学会,中华医学杂志社,中华医学会全科医学分会,等. 高血压基层诊疗指南(2019年)[J].中华全科医师杂志,2019,18(4):301-313. DOI:10.3760/cma.j.issn.1671-7368.2019.04.002.
|
| [29] |
张卫芳,谢珊珊,苏海. 血管内皮生长因子抑制剂相关高血压的治疗和管理[J]. 中华高血压杂志,2023,31(1):27-33. DOI:10.16439/j.issn.1673-7245.2023.01.009.
|
| [30] |
|
| [31] |
中国临床肿瘤学会指南工作委员会组织. 中国临床肿瘤学会(CSCO)肿瘤心脏病学临床实践指南-2023[M]. 北京:人民卫生出版社,2023.
|
| [32] |
|
| [33] |
|
| [34] |
|
| [35] |
|
| [1] | TIAN Chen, LIU Jianing, TIAN Jinhui, GE Long. Living Systematic Reviews: Methods and Processes for Development [J]. Chinese General Practice, 2025, 28(30): 3853-3860. |
| [2] | WANG Tingting, TANG Yong, ZHANG Wenke, LI Zhigang. Research Progress on Exercise Intervention of Hyperuricemia [J]. Chinese General Practice, 2025, 28(30): 3841-3846. |
| [3] | XU Jialan, YAN Hong, WEN Jun, ZHOU Zitong, WANG Siyu. Prevalence of Potentially Inappropriate Medication in Older Adults with Cancer: a Meta-analysis [J]. Chinese General Practice, 2025, 28(30): 3815-3822. |
| [4] | LI Hao, LI Peijin, LIU Tingting, CUI Yiyuan, LI Sicong, LIU Lixing, FENG Li, Working Group on Integrated Traditional Chinese and Western Medicine Diagnosis and Treatment Guidelines for Cancer Pain. Guidelines on the Diagnosis and Treatment of Cancer Pain by Integrated Traditional Chinese and Western Medicine [J]. Chinese General Practice, 2025, 28(30): 3729-3740. |
| [5] | ZHOU Sheng, DENG Changsheng, ZOU Guanyang, SONG Jianping. Research Progress on the Pathogenesis of Complications of Malaria in Cardiovascular Diseases [J]. Chinese General Practice, 2025, 28(27): 3466-3472. |
| [6] | CUI Yiyuan, YAN Yijing, WANG Ying, MENG Xiangju, ZHANG Qinglin, LIU Lixing, LI Sicong, FENG Li, The Working Group for the Clinical Practice Guideline for the Cancer-related Fatigue with Integrated Traditional Chinese and Western Medicine. Clinical Practice Guideline for the Integrated Traditional Chinese and Western Medicine Diagnosis and Treatment of Cancer-related Fatigue [J]. Chinese General Practice, 2025, 28(27): 3345-3358. |
| [7] | WANG Yajing, DUAN Xiaoyang, HOU Ran, HUANG Yajie, SHI Jian. Advances in Targeted Combination Therapy for Patients with Brain Metastases from EGFR-mutated Non-small Cell Lung Cancer [J]. Chinese General Practice, 2025, 28(26): 3328-3337. |
| [8] | HUANG Yulin, WANG Haoyun, LI Yanmei, XIAO Xueying. Symptom Clusters in Gastric Cancer Patients Receiving Chemotherapy: a Scoping Review [J]. Chinese General Practice, 2025, 28(26): 3338-3344. |
| [9] | SHANG Zhonghua, JIANG Zhiyue, HUANG Zhaohui, YANG Xing, LIU Haiyan, ZHANG Li. Trends in Cervical Cancer Burden in China from 1990 to 2021 and Prediction for 2022 to 2035 [J]. Chinese General Practice, 2025, 28(26): 3314-3320. |
| [10] | YANG Chen, CHEN Tong, ZHANG Lifang, ZHANG Hongxu, LI Pengfei, ZHANG Xuejuan. Prognostic Impact of Dapagliflozin in Elderly Breast Cancer Survivors with Heart Failure with Preserved Ejection Fraction and Type 2 Diabetes [J]. Chinese General Practice, 2025, 28(24): 3053-3058. |
| [11] | LIU Yinyin, SUI Hongping, LI Tingting, JIANG Tongtong, SHI Tieying, XIA Yunlong. Advances in Risk Prediction Models for Cardiotoxicity Associated with Breast Cancer Treatment [J]. Chinese General Practice, 2025, 28(24): 3072-3078. |
| [12] | LI Miaoxiu, ZHU Bowen, KONG Lingjun, FANG Min. Progress in Research on Clinical Assessment Tools for Conservative Treatment of Adolescent Idiopathic Scoliosis [J]. Chinese General Practice, 2025, 28(24): 3079-3088. |
| [13] | XIAO Yao, WAN Jun. Treatment of Venous Thromboembolism in Special Populations with Direct Oral Anticoagulants [J]. Chinese General Practice, 2025, 28(24): 3066-3071. |
| [14] | WANG Xiaolin, LI Qiuyue, ZHOU Yanjun, ZHANG Jinhui, LIANG Tao. Incidence and Risk of Cardiovascular Toxicity with Fruquintinib in Metastatic Colorectal Cancer: a Meta-analysis [J]. Chinese General Practice, 2025, 28(23): 2934-2940. |
| [15] | RUAN Wanbai, LI Junfeng, YIN Yanmei, PENG Lei, ZHU Kexiang. Research Progress of Targeted Therapy and Immunotherapy for Pancreatic Cancer [J]. Chinese General Practice, 2025, 28(23): 2950-2960. |
| Viewed | ||||||
|
Full text |
|
|||||
|
Abstract |
|
|||||